CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2004-09-29): Interferon and cirrhosis tied to liver failure in HIV/HCV coinfection


Interferon and cirrhosis tied to liver failure in HIV/HCV coinfection

Last Updated: 2004-09-29 15:37:23 -0400 (Reuters Health)

NEW YORK (Reuters Health) - In patients coinfected with HIV and hepatitis C virus (HCV), and who are also affected by cirrhosis, treatment with interferon (IFN) raises the risk of hepatic decompensation, according to German researchers.

However, this does not necessarily mean that interferon-based therapy should be avoided, Dr. Stefan Mauss and colleagues write in the September 3rd issue of AIDS. Instead, "coinfected patients with histological progression of their chronic hepatitis C should be considered for interferon-based treatment before they develop late stage liver disease."

Dr. Mauss, at the Center for HIV and Hepatogastroenterology in Dusseldorf, and colleagues observed 14 cases of hepatic decompensation among 123 cirrhotic patients enrolled in a clinical trial comparing treatment with peg-IFN alpha-2a or conventional IFN alpha-2a, with or without ribavirin.

Decomposition set in within 24 weeks and was not observed in trial participants who did not have cirrhosis. There was no increase in HCV RNA before decompensation developed.

Multivariate analysis revealed five risk factors associated with hepatic decompensation: increased bilirubin, decreased hemoglobin, increased alkaline phosphatase or decreased platelets, and treatment with didanosine.

Markers of viral replication, histological activity, treatments for hepatitis C, or CD4-positive cell counts were not associated with hepatic decompensation. Treatment with ribavirin or peg-IFN versus conventional IFN did not affect outcomes.

Dr. Mauss's team advises that didanosine be avoided in patients with advanced liver disease. However, these patients should not be excluded from interferon-based therapy, given their lack of options. They should nonetheless be monitored closely.

AIDS 2004;18:F21-F25.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Live CME Meetings
Slide Library
Abstract Library
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Regional Map
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2015 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.